On World Arthritis Day, TOGETHER-PsA data and 3 rheumatology/derm experts frame GLP-1 agonists as a promising — but not yet proven — adjunct therapy.
News|Articles|July 10, 2024
Clinical Quiz: Active Oligoarthritis Treatment Recommendations from 2021 ACR JIA Guidelines
Author(s)HCPLive Editorial Staff
Test your knowledge of active oligoarthritis treatment recommendations from the 2021 ACR guideline on JIA with this quiz.
Advertisement
Oligoarthritis, characterized as
In the first in a series of clinical quizzes based on the American College of Rheumatology’s 2021 Guideline for the Treatment of Juvenile Idiopathic Arthritis, we focus on initial and subsequent treatment recommendations for patients with active oligoarthritis.
What is the recommended initial therapy for active oligoarthritis in JIA?
Advertisement
Related to this article
At Week 52, ixekizumab plus tirzepatide sustained gains in skin clearance, joint response and metabolic measures versus ixekizumab alone.
Werth discusses what the 52-week AMETHYST Part A data add to the case for litifilimab in antimalarial-refractory cutaneous lupus erythematosus.
Amplio Pharma now planning a phase 2a study after NovoBioJect raised intracellular active methotrexate levels by 38%.
The EC approved upadacitinib for active polyarticular JIA in children 2 years and older, based on phase 1 SELECT-YOUTH efficacy and safety data.
Amgen reported dazodalibep met its primary endpoint in the phase 3 OASIZ-301 trial, improving ESSDAI score in moderate-to-severe systemic Sjögren's disease.
Rozanolixizumab improved FIQR score at 10 weeks but did not reach 2-sided statistical significance on its primary BPI-SF interference endpoint.
Two-year data from the open-label extension show sustained ACR and MDA response rates for the TYK2 inhibitor in active psoriatic arthritis.
Advertisement
Advertisement